This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the topline results for Uplinza (inebilizumab) for treatment of Immunoglobin G4-related disease (IgG4-RD)

Ticker(s): AMGN

Who's the expert?

Institution: Mayo Clinic 

  • Rheumatologists at the Mayo Clinic in Jacksonville Florida with a treatment focus on Vasculitis, Behcets, Rheumatoid Arthritis, and Gout. 
  • Currently manages 40 patients with rheumatoid arthritis and has read through the phase 1 early stage data regarding KPL-404.
  • Research focuses on Rheumatoid Arthritis, Lupus, and Vasculitis.

Interview Goal
Discuss SoC for IgG4-RD and potential of CD19 mAbs to treat this indication

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.